Malvidin chloride

CAS No. 643-84-5

Malvidin chloride( —— )

Catalog No. M31183 CAS No. 643-84-5

Malvidin chloride has anti-spermatogenic, and antioxidant activities. It can prevent endothelial dysfunction by inhibiting ROS and XO-1.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 351 In Stock
50MG Get Quote In Stock
100MG Get Quote In Stock

Biological Information

  • Product Name
    Malvidin chloride
  • Note
    Research use only, not for human use.
  • Brief Description
    Malvidin chloride has anti-spermatogenic, and antioxidant activities. It can prevent endothelial dysfunction by inhibiting ROS and XO-1.
  • Description
    Malvidin chloride has anti-spermatogenic, and antioxidant activities. It can prevent endothelial dysfunction by inhibiting ROS and XO-1.
  • In Vitro
    Malvidin (0~80 μg/mL; 96 hours; U937 cells) shows cytotoxic activity in a dose-dependent pattern.The IC50 value of Malvidin for U937 cells is 40 μg/mL. Malvidin (U937 cells) shows arrest at the G2/M phase of the cell cycle and increases sub G1 hypo-diploid population.Cell Viability Assay Cell Line:U937 cells Concentration:0~80 μg/mL Incubation Time:96 hours Result:Showed cytotoxic activity in a dose-dependent pattern.
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    643-84-5
  • Formula Weight
    366.8
  • Molecular Formula
    C17H15ClO7
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Protionamide

    Protionamide (or prothionamide) is a drug used in the treatment of tuberculosis.

  • MRT-2359

    MRT-2359 is a potent and orally available GSPT1 reducer with antitumour activity.MRT-2359 inhibits the growth of drug-resistant non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) cells.MRT-2359 exhibits preferential activity in MYC-driven cell lines.

  • Atractylenolide III

    Atractylenolide III may have therapeutic potential in treating homocysteine-mediated cognitive impairment and neuronal injury.